Topic: National Cancer Research Network
Conditions
Interventions
Blood sampling, [3 x 10 ml whole blood collected in greentopped (heparinised) tube] will be collected at baseline (within 14 days prior to first dose), on day 1 (immediately preceding chemotherapy), d
Sponsors
Imperial College of Science, Technology and Medicine (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Female at least 18 years of age at the time of signing the informed consent form 2. Capable of giving written informed consent 3. Having measurable tumour tissue and Platinum-resistant ovarian cancer as defined as radiological evidence of disease progression within 6 months of completion of platinum-containing chemotherapy 4. Tumour tissue measuring >2cm long axis amenable to direct biopsy or biopsy via image-guidance
Exclusion criteria
Exclusion criteria: Concurrent medication with warfarin or low molecular weight heparin (heparin use is acceptable if it has been discontinued for 2 days preceding biopsy)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Response, CA125 response and Progression free survival measured by ELISA detected decrease in phosphorylated PRAS40 (as ratio of total PRAS40) and increase in pAKT S473 | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed